Q4 2023 EPS Estimates for ProQR Therapeutics (NASDAQ:PRQR) Decreased by HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR – Get Rating) – Investment analysts at HC Wainwright lowered their Q4 2023 EPS estimates for ProQR Therapeutics in a research note issued on Wednesday, May 17th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $0.36 for the quarter, down from their prior forecast of $0.38. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.29) per share.

ProQR Therapeutics (NASDAQ:PRQR – Get Rating) last posted its quarterly earnings results on Wednesday, March 29th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $0.84 million during the quarter, compared to analysts’ expectations of $1.00 million. ProQR Therapeutics had a negative net margin of 1,707.31% and a negative return on equity of 81.48%.

Other research analysts have also recently issued reports about the stock. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 12th. Citigroup dropped their price target on shares of ProQR Therapeutics from $3.00 to $2.25 in a research report on Friday, April 7th. JMP Securities raised shares of ProQR Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the company from $1.50 to $5.00 in a research report on Thursday, March 30th. Finally, Cantor Fitzgerald lowered their price objective on shares of ProQR Therapeutics from $5.00 to $4.50 in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.35.

ProQR Therapeutics Trading Down 0.6 %

NASDAQ:PRQR opened at $1.74 on Thursday. The stock has a market capitalization of $140.63 million, a price-to-earnings ratio of -1.85 and a beta of 0.05. The firm has a fifty day simple moving average of $2.45 and a two-hundred day simple moving average of $2.37. ProQR Therapeutics has a 12 month low of $0.59 and a 12 month high of $3.85. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds have recently bought and sold shares of the company. EcoR1 Capital LLC purchased a new position in ProQR Therapeutics during the first quarter valued at approximately $6,183,000. M28 Capital Management LP grew its stake in ProQR Therapeutics by 90.7% during the fourth quarter. M28 Capital Management LP now owns 1,910,600 shares of the biopharmaceutical company’s stock valued at $7,069,000 after acquiring an additional 908,800 shares in the last quarter. JPMorgan Chase & Co. grew its stake in ProQR Therapeutics by 37.8% during the first quarter. JPMorgan Chase & Co. now owns 977,794 shares of the biopharmaceutical company’s stock valued at $885,000 after acquiring an additional 268,315 shares in the last quarter. Renaissance Technologies LLC grew its stake in ProQR Therapeutics by 53.8% during the second quarter. Renaissance Technologies LLC now owns 929,000 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 324,819 shares in the last quarter. Finally, BlackRock Inc. grew its stake in ProQR Therapeutics by 8.1% in the 1st quarter. BlackRock Inc. now owns 527,396 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 39,482 shares in the last quarter. Hedge funds and other institutional investors own 29.79% of the company’s stock.

About ProQR Therapeutics

(Get Rating)

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.